Mitotic kinesin inhibitors

Details for Australian Patent Application No. 2004266629 (hide)

Owner Merck & Co., Inc.

Inventors Cox, Christopher D.; Coleman, Paul J.

Agent Spruson & Ferguson

Pub. Number AU-B-2004266629

PCT Pub. Number WO2005/018547

Priority 60/495,735 15.08.03 US

Filing date 11 August 2004

Wipo publication date 3 March 2005

Acceptance publication date 26 November 2009

International Classifications

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 35/00 (2006.01) Antineoplastic agents

C07D 403/00 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

2 March 2006 PCT application entered the National Phase

  PCT publication WO2005/018547 Priority application(s): WO2005/018547

26 November 2009 Application Accepted

  Published as AU-B-2004266629

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp. Amendments

25 March 2010 Standard Patent Sealed

8 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004266632-Use of polypeptides of the cupredoxin family in cancer therapy

2004266623-Self-etching dental compositions and methods